What are the limits in the fight against obesity? Ozempic owner disappoints the market
Briefly

from english.elpais.com2 weeks ago
"Novo Nordisk, once the leader in obesity treatments with Ozempic, is now grappling with intense competition as new drugs emerge, potentially impacting its market dominance."
english.elpais.comhttps://english.elpais.com/economy-and-business/2025-01-18/what-are-the-limits-in-the-fight-against-obesity-ozempic-owner-disappoints-the-market.html
"CagriSema's average weight loss result of 22.7% was seen as a letdown by investors, raising concerns about Novo Nordisk's future amidst rising competition from Eli Lilly."
english.elpais.comhttps://english.elpais.com/economy-and-business/2025-01-18/what-are-the-limits-in-the-fight-against-obesity-ozempic-owner-disappoints-the-market.html
Read at english.elpais.com
#novo-nordisk #ozempic #cagrisema #obesity-treatment #market-competition
[
|
]